These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Assessing the validity of clinical trials. Akobeng AK J Pediatr Gastroenterol Nutr; 2008 Sep; 47(3):277-82. PubMed ID: 18728521 [TBL] [Abstract][Full Text] [Related]
4. New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence. Virgili G; Do DV; Bressler NM; Menchini U Acta Ophthalmol Scand; 2007 Feb; 85(1):6-20. PubMed ID: 17244204 [TBL] [Abstract][Full Text] [Related]
6. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
7. How to perform a critical analysis of a randomised controlled trial. Estellat C; Torgerson DJ; Ravaud P Best Pract Res Clin Rheumatol; 2009 Apr; 23(2):291-303. PubMed ID: 19393572 [TBL] [Abstract][Full Text] [Related]
8. The burden of age-related macular degeneration: a value-based analysis. Brown MM; Brown GC; Sharma S; Stein JD; Roth Z; Campanella J; Beauchamp GR Curr Opin Ophthalmol; 2006 Jun; 17(3):257-66. PubMed ID: 16794438 [TBL] [Abstract][Full Text] [Related]
9. Examination of external validity in randomized controlled trials for adjuvant treatment of pancreatic adenocarcinoma. Sorg C; Schmidt J; Büchler MW; Edler L; Märten A Pancreas; 2009 Jul; 38(5):542-50. PubMed ID: 19287330 [TBL] [Abstract][Full Text] [Related]
10. [Critical evaluation of clinical trials]. Gulácsi L; Kiss I Orv Hetil; 2004 Dec; 145(51):2575-81. PubMed ID: 15715291 [TBL] [Abstract][Full Text] [Related]
11. Redefining the randomized controlled trial in the context of acupuncture research. Walji R; Boon H Complement Ther Clin Pract; 2006 May; 12(2):91-6. PubMed ID: 16648085 [TBL] [Abstract][Full Text] [Related]
12. Basics of methodologic analysis of therapeutic trials. Part III: applicability of the results to the individual patient. Soares I; Carneiro AV Rev Port Cardiol; 2002 Jun; 21(6):783-95. PubMed ID: 12194379 [TBL] [Abstract][Full Text] [Related]
13. How to anticipate the assessment of the public health benefit of new medicines? Massol J; Puech A; Boissel JP; Therapie; 2007; 62(5):427-35. PubMed ID: 18206104 [TBL] [Abstract][Full Text] [Related]
14. Problems in the conduct and analysis of randomized clinical trials. Are we getting the right answers to the wrong questions? Rabeneck L; Viscoli CM; Horwitz RI Arch Intern Med; 1992 Mar; 152(3):507-12. PubMed ID: 1546913 [TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Greenfield S; Kravitz R; Duan N; Kaplan SH Am J Med; 2007 Apr; 120(4 Suppl 1):S3-9. PubMed ID: 17403380 [TBL] [Abstract][Full Text] [Related]
17. [Procedures and methods of benefit assessments for medicines in Germany]. Bekkering GE; Kleijnen J Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813 [TBL] [Abstract][Full Text] [Related]
18. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Brown MM; Brown GC; Brown HC; Peet J Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724 [TBL] [Abstract][Full Text] [Related]
19. The Fox guarding the clinical trial: internal vs. external validity in randomized studies. Goodwin PJ; Pritchard KI; Spiegel D Psychooncology; 1999; 8(3):275. PubMed ID: 10390742 [No Abstract] [Full Text] [Related]
20. Basics of methodologic analysis of therapeutic trials. Part II: Importance of the results. Soares I; Carneiro AV Rev Port Cardiol; 2002 May; 21(5):613-26. PubMed ID: 12174523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]